Memantine in Adult Autism Spectrum Disorder

• Status: Terminated
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to see if memantine is helpful in managing problematic symptoms in adults with autism, Asperger's disorder, or Pervasive Developmental Disorder not otherwise specified (NOS).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborator: Forest Laboratories
• Treatments: Memantine

Criteria

Inclusion criteria

• Participant is currently in treatment in the Johns Hopkins Bayview Medical Center (JHBMC)

• Participant has a diagnosis of:

• Autistic Disorder

• Asperger's Disorder

• Pervasive Developmental Disorder (PDD) NOS

• Participant meets one of the following criteria:

• CGI-S >= 4 (CGI-S: ________)

• Participant has the following problematic behaviors (at least one) that might be expected to benefit from memantine:

1. _____________________________________________

2. _____________________________________________

3. _____________________________________________

Exclusion criteria

The patient meets none of the following criteria (mark if absent):

• Active seizures (Patients with a history of seizures, who have been seizure-free on an antiepileptic regimen for six months or more would be eligible).

• Rett's Syndrome or Childhood Disintegrative Disorder

• Active treatment with an acetylcholinesterase inhibitor

• Prior or current treatment with memantine

• Current treatment with lamotrigine

• Genetic, metabolic or degenerative disorder (excepting Fragile X).

• Brain malformation or known severe brain trauma

• Pregnancy or breastfeeding

• Glomerular Filtration Rate (GFR) < 30 mL/min